- Home
- LNAI vs QNME Comparison
LNAI vs QNME Comparison
Compare LNAI & QNME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LNAI | QNME |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Integrated Freight & Logistics |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.4M | 11.4M |
| IPO Year | 2014 | 2024 |
Fundamental Metrics
Financial Performance| Metric | LNAI | QNME |
|---|---|---|
| Price | $1.42 | $0.53 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 36.4K | ★ 19.9M |
| Earning Date | 11-13-2026 | 09-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 47.83 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,850,681.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 111.79 |
| 52 Week Low | $0.15 | $0.26 |
| 52 Week High | $5.02 | $1.40 |
Technical Indicators
Market Signals| Indicator | LNAI | QNME |
|---|---|---|
| Relative Strength Index (RSI) | 25.99 | 54.93 |
| Support Level | $0.26 | $0.29 |
| Resistance Level | $2.58 | $1.40 |
| Average True Range (ATR) | 0.25 | 0.18 |
| MACD | -0.08 | 0.01 |
| Stochastic Oscillator | 7.39 | 29.44 |
Price Performance
Historical ComparisonAbout LNAI Lunai Bioworks Inc.
Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.
About QNME Quanome Technologies Inc. Common Stock
Quanome Technologies Inc is a U.S.-based integrated cross-border supply chain solution provider with a strategic focus on the Asian market including China and South Korea.